Neuromagen Pharma Announces the Appointment of Professor Gal Ifergane, Head of the Neurology Department at Soroka Medical Center, to its Scientific Advisory Board
#Partners #Management Changes
May 5, 2022
www.biospace.com
Neuromagen Pharma Ltd. Receives FDA Orphan Drug Designation for its AGS-499 Drug Candidate to Slow the Progression of ALS (Amyotrophic Lateral Sclerosis) | BioSpace
#Customers #Partners
Mar 21, 2022
www.prnewswire.com
Neuromagen Pharma Announces the Approval of a NIS 1.8M Budget from the Israel Innovation Authority R&D Fund Incentive Program
#Investment
Feb 8, 2022
www.prnewswire.com
Neuromagen Pharma to Present at the BIO-Europe Spring 2022 Conference
#Partners #Expand
Nov 2, 2021
www-timesofisrael-com.cdn.ampproject.org
Israeli drug that slowed Alzheimer's, ALS in mice gets funding to start trials
Neuromagen Pharma Announces the Appointment of Professor Gal Ifergane, Head of the Neurology Department at Soroka Medical Center, to its Scientific Advisory Board
#Partners #Management Changes
May 5, 2022
www.biospace.com
Neuromagen Pharma Ltd. Receives FDA Orphan Drug Designation for its AGS-499 Drug Candidate to Slow the Progression of ALS (Amyotrophic Lateral Sclerosis) | BioSpace
#Customers #Partners
Mar 21, 2022
www.prnewswire.com
Neuromagen Pharma Announces the Approval of a NIS 1.8M Budget from the Israel Innovation Authority R&D Fund Incentive Program
#Investment
Feb 8, 2022
www.prnewswire.com
Neuromagen Pharma to Present at the BIO-Europe Spring 2022 Conference
#Partners #Expand
Nov 2, 2021
www-timesofisrael-com.cdn.ampproject.org
Israeli drug that slowed Alzheimer's, ALS in mice gets funding to start trials